Sachiko kodama biography of martin luther king
•
Editors
Scientific Reports is run by a team of experienced editors who are experts in their fields. From our Editorial Board Members and Senior Editorial Board to our in-house Editors, we work togetherResearch integrity issue to ensure that your research is expertly handled and that we consider it to be technically sound, scientifically valid, and ultimately suitable for publication.
Interview with Rafal Marszalek, Chief Editor of Scientific Reports
In-house Editors
Chief Editor: Rafal Marszalek, PhD; Springer Nature, UK
Rafal's background is analytical and biological chemistry. He did his PhD and postdoctoral research in single-cell proteomics at Imperial College London, UK. He was an editor at Genome Biology before joining Scientific Reports in August
ORCID
Deputy Editor: Elizabeth Mann, PhD; Springer Nature, UK
Elizabeth has a background in pharmacology and completed her PhD in neuropharmacology at King's College London, UK. She joi
•
Records of the Army personal (Record Group )
Investigative Records Repository (IRR)
Personal Name Files,
Where to find these files:: National Archives in College Park, Maryland, in /84/01/01 - /84/19/
| Box # | Last Name | First Name | File Number | Note |
|---|---|---|---|---|
| 1 | ABASLON | Gunther | XE | |
| 1 | ABBOTT | Samuel W. | X | |
| 1 | ABE | Den | XA | |
| 1 | ABE | Hiroshi | XA | |
| 1 | ABE | Itaru | XA | |
| 1 | ABE | Koichi | XA | |
| 1 | ABE | Tadaichi | XA | |
| 1 | ABE | Yoshiko | G | |
| 1 | ABE | Yoshimi | XA | |
| 1 | ABE | Yoshio | XA | |
| 1 | ABEGG | Lily Hermine | XA | |
| 1 | ABEL | Karl | DE | |
| 10 | ALBRECHT | Karl L. | XE | |
| 10 | ALBRECHT | Otto | XE | |
| 10 | ALBRECHT | Siegfried | HE | |
| 10 | ALBRECHT | Wilhelm | XE | |
| 10 | ALCORN | Julian Thomas | C | |
| 10 | A • Why was the cohort study set up?Although a large sample size is useful for the elucidation of what is called ‘missing heritability’, which is an unexplained part of a total phenotypic variance in a quantitative trait or familial disease aggregation, in prospective genome cohort studies, additional strategies may be required.1 Historically, many patient-based cohort studies have been conducted with limited environmental information for the period preceding the onset of diseases.2–6 Population-based prospective cohort designs have since been improved, and many risk factors for diseases have been identified.7–10 Once the importance of in utero exposures was recognized, birth cohorts were also developed,11–18 and were used to examine the lifelong effects of in utero exposures.19 Because a study assessing disease risk throughout a person’s lifespan requires exposure and outcome measurements in multiple generations with long-term follow-up, a three-generation prospective c |